chrisvoncsefalvay/vaers-outcomes huggingface dataset:
4 days after the second vaccine in injection I had the same overall feeling once; next week I am having an increasingly "heavy" feeling to my right arm and leg; right side feel heavy or almost numb; I am still able to use the arm and leg but it feels difficult to move.; This has progressed to a periodic numbness to the right hand and bottom of right foot; numbness in both hands off and on; This is a spontaneous report from a contactable nurse (patient herself). A 38-years-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, lot number: EL9261), via intramuscular route of administration in Arm Left on 25Jan2021 at 09:00 (38-years-old at the time of vaccination) as single dose for covid-19 immunisation. Medical history included migraines, PFO with closure, stroke, PNA 2002, headaches, covid-19 (patient had covid prior vaccination). No known allergies were reported. Patient did not receive other vaccine in four weeks. Concomitant medication(s) included ASA taken for an unspecified indication, start and stop date were not reported; ibuprofen taken for headache, start and stop date were not reported. The patient was not pregnant at the time of vaccination. The patient previously received first dose of bnt162b2 (lot number: EK4176) via intramuscular route of administration in Arm Left on 04Jan2021 at 12:00 (38-years-old at the time of vaccination) as single dose for covid-19 immunisation and had an episode of right leg numbness and an overall odd' feeling throughout her entire body that subsided in about 5 minutes. On an unspecified date in Jan2021, 4 days after the second vaccine, the patient had the same overall feeling (like first dose) once, while at work, that made right side feel heavy or almost numb. It persisted for a few hours and subsided. The next week patient had an increasingly heavy' feeling to right arm and leg. It was periodic but seems to be progressing to a constant heavy feeling. Patient was still able to use the arm and leg, but it feels difficult to move. This has progressed to a periodic numbness to the right hand and bottom of right foot. Also, when sleeping patient was getting numbness in both hands off and on. Events resulted in visit doctor or other healthcare professional office/clinic visit for events. It was unknown if patient received treatment for the events. Patient was not tested covid post vaccination. The outcome of events was not resolved.  Follow-up attempts completed. No further information expected.
Began with pain at injection site when I went to bed; difficulty sleeping; awoke 10/08 and noticed redness around the injection site. Felt ill all day; redness appeared to get worse during the day and pain was almost intolerable. Three days later I felt better, but then the 4th day, the pain, redness and discomfort continued with feeling ill.  Reported to doctor and was told problem is typical with pneumonia shot.  I also received a flu shot the same day as pneumonia shot but that arm had no reaction.  Today is Nov. 8th and I still have lump at injection site of pneumonia shot.
mom states p/leaving clinic pt turned blue around lips, ears, hands now fever 104.2 taken to ER given APAP; given tepid bath;
swelling of both legs; This case was reported by a consumer via call center representative and described the occurrence of swelling of legs in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of no adverse event (received 1st dose on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, 1 week after receiving Shingrix, the patient experienced swelling of legs. On an unknown date, the outcome of the swelling of legs was unknown.   It was unknown if the reporter considered the swelling of legs to be related to Shingrix.  Additional details were provided as follows: Age at vaccination was not reported. The patient reported that one week after dose 2, she experienced swelling of both legs. The patient did not have dates.   The reporter did not consent to follow-up.
HEADACHES REGULARLY; HANDS, ARMS AND FEET NUMB RANDOMLY ALMOST EVERYDAY; TINGLING IN VACCINATED ARM; GAIN SIGNIFICANT AMOUNT OF WEIGHT; This spontaneous report received from a patient concerned a 4 decade old of unspecified sex. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included: The patient was very healthy entire life. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose was not reported, administered on 02-NOV-2021 for prophylactic vaccination. The batch number was not reported and has been requested. Age at time of vaccination 4 decade old. No concomitant medications were reported.  On NOV-2021, the patient experienced gain significant amount of weight. On 02-NOV-2021, the patient experienced tingling in vaccinated arm, and hands, arms and feet numb randomly almost everyday. On an unspecified date, the patient experienced headaches regularly. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from headaches regularly, and hands, arms and feet numb randomly almost everyday, and the outcome of tingling in vaccinated arm and gain significant amount of weight was not reported. This report was non-serious.
Rash on upper chest and back and itching.  Have not reported reaction to primary care doctor.
Moderna vaccine (NDC 80777-0273-98) lot# 039D21A * GTIN 003807772739v83 was administered after the beyond date of 10/23/2021. Contacted Manufacturer Moderna= no need to repeat the dose   .
t99.6 on 17DEC nausea, diarrhea, h/a, irritable the diarrhea & irritability has persisted still present 23DEC;
Patient was given Flu Mist & she has asthma.  She had the flu shot by her Pediatrician, 9/29/14.  This nurse went to the school to give Flu Mist & wrong student was asked to come to the office.  This nurse did not ask her her name.  Mom called @ 4:00 PM asking why her daughter had a Flu Mist.  This nurse called Dr. & his nurse told me to tell Mom to give patient Fluvent treatments bid over the weekend. If child wheezes to give albuterol rescue treatment.  This nurse gave Mom her phone # for her to call if any questions; and Dr's nurse said she could call them if any questions.
5/9/21 - noticed a lot of itching to the left upper back  saw 4 red bumps in a linear pattern. Along the  right side of neck just below the jaw line was a larger flatter reddened itchy spot 5/10/21- The rash began to spread to neck but became larger, inflamed, red, itchier with a few more to the left arm 5/11/21 - The rash became more hives with multiple large red circular raised lesion coalescing together, itchier and painful, warm to touch  5/12-5/14- The hives became larger on the left arm, across the upper back, back of neck, right arm, hands and  a few to both upper and lower legs. They were itchy and painful, red and warm to touch on the left arm, red and inflamed everywhere else.  The was a large one on the left elbow and caused stiffness to the joint.  The left arm to hand was swollen 5/15 - more hives occurred to the right arm and right upper leg, right knee,  right buttock, and right cheek.  All were itching, red and inflammation to the extremities  5/16/21 - The hives on the left arm were worse with more redness and swelling to the arm and generally throughout the body.  Both knees had large hives with redness, inflammation, itching and pain with stiffness inside the knee joint and difficulty bending the knee 5/17/21- The hives on the left arm reduce in size but continue to be red, inflamed, itchy and painful. New hives to the right arm, right and left legs, 4th toe of the right foot and 2nd toes of the left foot,  left wrist, and  right ring finger with redness, itching and pain.
The dose was expired (05/30/14), but patient did NOT suffer any ill effects from the vaccine. The dose was repeated on 03/07/2015 as per CDC guidelines.
PATIENT DESCRIBES:  1 MONTH FOLLOWING 2ND DOSE MODERNA- PLATELET COUNT 625 AFTER A BASELINE OF 236 IN 11/2020.  FOLLOWUP PLATELET COUNTS- 6/30/2021- 1684:   7/9/2021- 1566:  SEPT/ 2021- 1900.  DENIES ALL SYMPTOMS EXCEPT UNUSUAL TIREDNESS. EVALUATED BY HEMATOLOGIST-  DR.  AND DX GIVEN:  CHRONIC MYELOCYTIC LEUKEMIA.
Since receiving both doses of the shot I have developed a skin irritation under both devices. Red, itchy bumps.; Since receiving both doses of the shot I have developed a skin irritation under both devices. Red, itchy bumps.; Since receiving both doses of the shot I have developed a skin irritation under both devices. Red, itchy bumps.; This is a spontaneous report from a contactable consumer (patient). A patient of an unspecified age and gender received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Lot number and expiration date were not reported), via an unspecified route of administration, on an unspecified date as dose 1, single and dose 2, single for COVID-19 immunization. Medical history included type 1 diabetes using a continuous glucose monitors (CGM) and insulin pump. The patient's concomitant medications were not reported. Prior to vaccination, the patient had zero skin irritation from either device. After vaccination with both the doses, the patient developed a skin irritation under both devices which were red, itchy bumps on an unspecified date. The outcome of the events was unknown at the time of report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
covid 19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (covid 19) in a 30-year-old male patient who received mRNA-1273 (Spikevax) (batch no. ASKU) for COVID-19 prophylaxis.     No Medical History information was reported.  On an unknown date, the patient received second dose of mRNA-1273 (Spikevax) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced COVID-19 (covid 19). At the time of the report, COVID-19 (covid 19) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: Positive.  For mRNA-1273 (Spikevax) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.  Unknown if patient had received any other vaccines in the 4 weeks prior to COVID-19 vaccine.  The patient tested positive for covid and went to doctor to get medication. He only had 2 Moderna vaccines.   Treatment information was not provided.
SUSPECTED COVID-19 INFECTION; This spontaneous report received from a patient concerned a 55 year old female. The patient's height, and weight were not reported.  The patient's concurrent conditions included multiple sclerosis. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers, administered on 10-APR-2021 for prophylactic vaccination. Concomitant medications included ocrelizumab for multiple sclerosis.  On 29-APR-2021, the subject experienced suspected covid-19 infection. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from suspected covid-19 infection. This report was non-serious.; Sender's Comments: V0: Medical Assessment comment not required as per standard procedure as the case assessed as non-serious.
Shingrix dose to a 14-year-old patient instead of the HPV vaccine; Shingrix dose to a 14 year old patient today on 7/28/2023; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 14-year-old female patient who received Herpes zoster (Shingrix) (batch number 59C4, expiry date 04-AUG-2024) for prophylaxis.   Concomitant products included HEPATITIS A VACCINE (HAVRIX).   On 28-JUL-2023, the patient received Shingrix (left deltoid). On 28-JUL-2023, an unknown time after receiving Shingrix, the patient experienced wrong vaccine administered (Verbatim: Shingrix dose to a 14-year-old patient instead of the HPV vaccine) and inappropriate age at vaccine administration (Verbatim: Shingrix dose to a 14 year old patient today on 7/28/2023). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown.   Additional Information: GSK Receipt Date: 28-JUL-2023 The reporter was a medical assistant. The reporter called to inquire that what to look for the patient. The reporter mentioned that the patient received a Havrix dose as well at the time of reporting.  The reporter did not consent to follow-up. The reporter reported that they inadvertently administered that was intended, which led to wrong vaccine administered and inappropriate age at vaccine administration.
EXTREMELY LARGE WELT AT SITE OF INJECTION WITH SEVERE ITCHING AND THE FORMATION OF COLD SORES ON UPPER LIP
BP 225/109; heart rate 52; This is a spontaneous report from a contactable consumer (patient). A 76-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE lot number and expiry date: Not available/provided by the reporter at the time of report) via an unspecified route of administration on 10Feb2021 (Wednesday) at single dose for Covid-19 immunization. The patient is vaccinated in a hospital. Medical history included that the patient does have a history of high blood pressure and takes clonidine twice a day. The patient previously took first dose of bnt162b2 on unspecified date at the hospital for covid-19 immunization; and previously took clonidine on unspecified date for high blood pressure. It was reported that late on 11Feb2021 she texted her symptoms, BP 225/109, heart rate 52 and temp. 99.1. She had notified her doctor who gave her instructions to help her BP. The events took place after use of product. The outcome of the events was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient. A patient (no qualifiers provided) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: ALOPECIA (non-serious), outcome "unknown", described as "Substantial hair loss". Additional Information: Since receiving the first dose of vaccine patient have noticed SUBSTANIAL hair loss, did not have this problem before the vaccine. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
child recv vax & lab eval revealed that pt (mom of child)  had no immunity to varicella zoster virus; pt devel a rash of vesicles on back, chest & face w/assoc fever;pt presented to MD & was dx w/varicella like rash;reporter felt sec trans
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of unknown age. Medical history, concurrent conditions, and concomitant medications were not provided. During 2016, the patient was inoculated (by an unspecified healthcare professional person) with ZOSTAVAX at a health care center as recommended for routine adult health maintenance for the prevention of shingles (dose, route of administration, site of administration and lot # were not provided). The vaccine did not prevent shingles as intended, but rather caused the patient to contract a persistent strain of herpes zoster. During 2016, the patient was treated (by an unspecified healthcare professional) at a physicians' practice for a persistent and severe vesicular rash accompanied by weakened immune symptoms which was diagnosed as herpes zoster, or shingles. As a direct and proximate result of these malfunctions, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown. The lawyer felt the events were related to ZOSTAVAX. Additional information has been requested.
The patient felt tired; This spontaneous case was reported by a patient and describes the occurrence of FATIGUE (The patient felt tired ) in a 76-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 057F22A) for COVID-19 prophylaxis.     No Medical History information was reported.  Concomitant products included LEVOTHYROXINE for an unknown indication.    On 07-Oct-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced FATIGUE (The patient felt tired ). At the time of the report, FATIGUE (The patient felt tired ) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   Patient was generally healthy.  No treatment information was reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-734615, US-MODERNATX, INC.-MOD-2023-734756 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-734615:Daughter's case US-MODERNATX, INC.-MOD-2023-734756:Husband's case
Injection site hot; injection site itchy; injfection site red; swollen area all the way up and down my arm; tender to touch; purple area; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (swollen area all the way up and down my arm), VACCINATION SITE WARMTH (Injection site hot), VACCINATION SITE DISCOLOURATION (purple area), VACCINATION SITE PRURITUS (injection site itchy) and VACCINATION SITE PAIN (tender to touch) in a 28-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. :0161321A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Complex regional pain syndrome. Concomitant products included DULOXETINE, CELECOXIB, METHOCARBAMOL and CLONAZEPAM for an unknown indication.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, the patient experienced VACCINATION SITE WARMTH (Injection site hot), VACCINATION SITE PRURITUS (injection site itchy) and VACCINATION SITE ERYTHEMA (injfection site red). In April 2021, the patient experienced PERIPHERAL SWELLING (swollen area all the way up and down my arm), VACCINATION SITE DISCOLOURATION (purple area) and VACCINATION SITE PAIN (tender to touch). At the time of the report, PERIPHERAL SWELLING (swollen area all the way up and down my arm), VACCINATION SITE WARMTH (Injection site hot), VACCINATION SITE DISCOLOURATION (purple area), VACCINATION SITE PRURITUS (injection site itchy), VACCINATION SITE PAIN (tender to touch) and VACCINATION SITE ERYTHEMA (injfection site red) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication was not provided.
Shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a male patient of an unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On an unspecified date in 2015, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot #, expiration date, dose, dose # and route not specified) for  the long term prevention of singles and zoster-related conditions. Subsequently on an unknown date, the patient was treated for singles. As a direct and proximate result of the patient's receipt of zoster vaccine live (ZOSTAVAX), the patient continued suffer ongoing injuries including but not limited to mental and physical pain and suffering, medical care and treatment for these injuries; significant medical and related expenses as medical losses and costs included care for hospitalization, physical care, monitoring, treatment, medications and supplies, diminished capacity for the enjoyment of life, diminished quality of life, increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions and other losses and damages; and will continue to suffer such losses, and damages in the future.The outcome of singles was not recovered. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).
could hardly walk/ Cannot walk very good; Legs heavy with fluid/legs filled heavy with fluid; Initial information received on 09-Feb-2023 regarding an unsolicited valid  courtesy non-serious case received via Pfizer from a consumer/non-hcp.  This case involves a 66 years old female patient (90.718 kg) whose legs heavy with fluid/legs filled heavy with fluid and could hardly walk/ cannot walk very good after receiving vaccine INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE (MIRAPEX); VITAMINS NOS (MULTIVITAMINS [VITAMINS NOS]); VITAMIN D NOS (VITAMIN D NOS); and COVID-19 VACCINE (COVID-19 VACCINE).  On an unknown date, the patient received an unknown dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE (strength, formulation, lot number and expiry date was unknown) via unknown route in unknown administration site for Prophylactic vaccination.  On 06-OCT-2022 the patient developed a non-serious event of  legs heavy with fluid/legs filled heavy with fluid (oedema peripheral) (latency: unknown) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  On an unknown date the patient developed a non-seriousevent of could hardly walk/ cannot walk very good (gait disturbance) (latency: unknown) following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  Action taken with QUADRIVALENT INFLUENZA VACCINE (FLUZONE HIGH-DOSE QUADRIVALENT) was not applicable.  It was not reported if the patient received a corrective treatment for the events.   Outcome: Not Recovered / Not Resolved for both events.